


























![]()
Q1: 2026-04-30 Earnings Summary
EPS of -$0.30 misses by $0.16
|
Revenue of
$164.90M
(4.89% Y/Y)
misses by $21.71M
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call April 30, 2026 5:00 PM EDT
Company Participants
Atabak Mokari - CFO & Treasurer
Sean Maduck - President of Endocrinology
Roberto Vieira - President of Oncology
Joseph K. Belanoff - Co-Founder, President, CEO & Director
William Guyer - Chief Development Officer
Conference Call Participants
David Amsellem - Piper Sandler & Co., Research Division
Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Thank you for standing by, and welcome to Corcept Therapeutics First Quarter 2026 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Atabak Mokari, CFO. Please go ahead.
Atabak Mokari
CFO & Treasurer
Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the first quarter and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC. Today's call is being recorded. A replay will be available at the Investors Past Events tab of our website.
Statements during this call other than statements of historical fact are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements expressed or implied. The risks and uncertainties that may affect our forward-looking statements are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q, which are available at the SEC's website. Please refer to those documents for more information. We disclaim any intention or duty to update forward-looking statements.
Our revenue in the first quarter of 2026 was $164.9 million compared to $157.2 million in the prior year period. We have increased our 2026 revenue guidance to $950 million to $1.05 billion. Net
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。